Targeted therapy for patients with renal-cell carcinoma

The Lancet Oncology

Volumn 12, Issue 12, 2011, Pages 1085-1087

  Rini, Brian I ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A5; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 8; MULTIDRUG RESISTANCE PROTEIN 1; PAZOPANIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; ETHNICITY; GENE; GENE SILENCING; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LETTER; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VON HIPPEL LINDAU GENE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN KINASE INHIBITORS; PYRROLES;

EID: 81255127528     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70276-5     Document Type: Letter

References (8)

1. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260:1317-1320.
2. Rini BI, Campbell SC, Escudier B Renal cell carcinoma. Lancet 2009, 373:1119-1132.
3. van der Veldt AA, Eechoute K, Gelderblom H, et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 2011, 17:620-629.
4. van Erp NP, Eechoute K, van der Veldt AA, et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 2009, 27:4406-4412.
5. Kim JJ, Vaziri SA, Rini BI, et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 2011, published online Aug 31. 10.1002/cncr.26491.
6. Xu CF, Bing NX, Ball HA, et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol 2011, 29:2557-2564.
7. Garcia-Donas J, Esteban E, Leandro-García LJ, et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 2011, published online Oct 18. 10.1016/S1470-2045(11)70266-2.
8. Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011, 103:763-773.